Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Terminated
Trial end date:
2020-06-16
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies enzalutamide in treating patients with mantle cell lymphoma
that has returned after a period of improvement (relapsed) or has not responded to previous
treatment (refractory). Androgens can cause the growth of cancer cells. Antihormone therapy,
such as enzalutamide, may lessen the amount of androgen made by the body.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
National Cancer Institute (NCI) National Comprehensive Cancer Network